Click HERE to download the PDF version

As it is widely known and reported by several clinical trials surveys, oncology keeps on being by far the most significant therapeutic area of interest for new drug developments, with an increasing trend over the last ten years.

Anticancer drugs are expected to account up to 35% of the total pharmaceutical pipeline in 2019 (source: Pharmaprojects®),
with a high level of interest specifically in the anticancer immunological category.

Within this framework, ICROM has decided to further invest in its drug substance high potency capabilities, expanding the existing manufacturing GMP unit in order to support the scale up of those HP NCE which are positively progressing in the clinical trials so to add more capacity for the new incoming as well as existing projects.

As it is sh ...